Company intelligence / Profile preview
Artizan Biosciences
New Haven, Connecticut, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Artizan Biosciences is advancing preclinical programs using its IgA-Seq platform to develop microbiome-targeted small molecule and live biotherapeutic therapies for chronic inflammatory diseases of the gut, with primary focus on inflammatory bowel disease. Clinical results are not yet available as lead programs are preclinical.
- Therapeutic areas
- GastroenterologyNeurology
- Modalities
- Small moleculeLive biotherapeutic product therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Biohaven TherapeuticsTrianni
Beyond the preview
Go deeper on Artizan Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Artizan Biosciences.